Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested in pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects and unwanted toxicity. Cambridge Healthtech Institute’s eighth annual event on Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family.
Get Free Registration to the CHI Discovery On Target Conference
Help us cover the Discovery On Target – HDAC Inhibitor meeting, and we’ll set you up with a complimentary registration. You just need to be able to attend the talks and write up a short report for our site. Contact us right away if you’d like to get involved.
>>Contact Us